Evidence map›Paper›PMID 41416491›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2025

Blood gene expression network expression strongly relates to brain amyloid burden.

Vaibhav A Janve, Mabel Seto, Reisa A Sperling, Paul S Aisen, Robert A Rissman, Mary Ellen I Koran, Logan Dumitrescu, Rachel F Buckley, Timothy J Hohman, A4 and LEARN Study Group

Abstract read
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Blood gene expression network expression strongly relates to brain amyloid burden.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Vaibhav A JanveVanderbilt Memory & Alzheimer's Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Mabel SetoCenter for Alzheimer Research and Treatment, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Reisa A SperlingCenter for Alzheimer's Research and Treatment, Brigham and Women's Hospital, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Paul S AisenAlzheimer's Therapeutic Research Institute, Keck School of Medicine, University of Southern California, San Diego, California, USA.
Robert A RissmanAlzheimer's Therapeutic Research Institute, Keck School of Medicine, University of Southern California, San Diego, California, USA.
Mary Ellen I KoranVanderbilt Memory & Alzheimer's Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Logan DumitrescuVanderbilt Memory & Alzheimer's Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Rachel F BuckleyCenter for Alzheimer Research and Treatment, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Timothy J HohmanVanderbilt Memory & Alzheimer's Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
A4 and LEARN Study GroupAlzheimer's Clinical Trial Consortium, Boston, Massachusetts, USA.

Funding

USCADRC Diversity Supplement PachicanoP30AG066530 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI HELENA Chang CHUI, ARTHUR W TOGA · 2020 to 2026
$27.8M
Systems Genetics Analysis of Sex Differences in Alzheimer's DiseaseR01AG074012 · NIA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI HARARI, OSCAR, HOHMAN, TIMOTHY J · 2021 to 2025
$6.2M
Neuroprotective Effects of Vascular Endothelial Growth Factor in Alzheimer's DiseaseR01AG061518 · NIA · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Timothy J Hohman · 2019 to 2026
$5.9M
Building predictive algorithms to identify resilience and resistance to Alzheimer's diseaseR01AG079142 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI Rachel Frances Buckley, Michael C Donohue · 2023 to 2026
$4.0M
The inactive X: discovering sex genes that influence female vulnerability to Alzheimer's diseaseDP2AG082342 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI Rachel Frances Buckley · 2022 to 2026
$2.5M
Accelerating Medicines PartnershipAlzheimer's AssociationEli Lilly and Co.GHR FoundationNational Institutes of Health-National Institute on AgingNIA NIH HHS DP2 AG082342NIA NIH HHS P30 AG066530NIA NIH HHS R01 AG061518NIA NIH HHS R01 AG074012NIA NIH HHS R01 AG079142
6 · The paper itself

Abstract

introductionAmyloid deposition occurs decades before symptoms emerge in Alzheimer's disease (AD). We leveraged blood transcriptomics and positron emission tomography (PET) measures of amyloidosis to identify gene networks in the blood that relate to amyloid burden in the brain.

methodsWhole-blood RNA sequencing and amyloid PET were leveraged from 1739 cognitively unimpaired participants in the Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) study. Linear regression related gene module expression to amyloid covarying for age, sex, education, and apolipoprotein E (APOE) ε2 and ε4 genotypes.

resultsOf the 18 gene modules, one histone gene cluster module was associated with amyloid (β = -0.55, false discovery rate-adjusted p value = 0.029). We also observed nominal associations for the predicted proportion of activated natural killer (NK) cells (β = -0.454, p = 0.02) and CD4+ activated memory T cells (β = -0.169, p = 0.03) with amyloid deposition. DISCUSSION: Our results implicate the histone gene cluster on chromosome 6 and immune cell proportions as blood correlates of brain amyloid deposition in preclinical AD. HIGHLIGHTS: Higher expression of network module with histone gene cluster on chromosome 6 associated with lower amyloid levels. Four histone genes, H1-5, H3C3, H2BC3, H2AC14, and RRM2, emerged as key genes driving this association, where H1-5 emerged as a hub gene for this module. Pathways, including nucleosome assembly and DNA damage, were enriched in the histone module. A higher fraction of activated NK and activated CD4+ T cells was related to lower amyloid burden.

Indexed as

Alzheimer DiseaseAmyloidAmyloidosisBrainGene Regulatory NetworksAgedAged, 80 and overFemaleHistonesHumansMalePositron-Emission TomographyAmyloidHistonesamyloid PETbulk RNA‐seqCD4+ activated memory T cellsCIBERSORTxdeconvolutiondigital cytometrygene expressionhistonenatural killer cellspreclinical ADp‐tau217WGCNAwhole blood

Identifiers

PMID41416491
PMCPMC12715697

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.